These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26116886)

  • 1. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
    Claveria-Cabello A; Colyn L; Arechederra M; Urman JM; Berasain C; Avila MA; Fernandez-Barrena MG
    Cells; 2020 Oct; 9(10):. PubMed ID: 33086678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
    Khan S; Ahirwar K; Jena G
    Epigenomics; 2016 Aug; 8(8):1087-101. PubMed ID: 27411759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
    Li X; Wu XQ; Xu T; Li XF; Yang Y; Li WX; Huang C; Meng XM; Li J
    Toxicol Appl Pharmacol; 2016 Sep; 306():58-68. PubMed ID: 27396813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
    Hyndman KA
    Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin H-Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells: Implications of Epigenetic Suppression of Matrix Metalloproteinases in Fibrosis through Stabilization of Class IIa Histone Deacetylases.
    Yang Z; Liu Y; Qin L; Wu P; Xia Z; Luo M; Zeng Y; Tsukamoto H; Ju Z; Su D; Kang H; Xiao Z; Zheng S; Duan Z; Hu R; Wang Q; Pandol SJ; Han YP
    Am J Pathol; 2017 Apr; 187(4):781-797. PubMed ID: 28157489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of HDAC inhibitors as cognitive enhancers.
    Gräff J; Tsai LH
    Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
    Lee CH; Choi Y; Cho H; Bang IH; Hao L; Lee SO; Jeon R; Bae EJ; Park BH
    Biochem Pharmacol; 2021 Jan; 183():114312. PubMed ID: 33130126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
    Zhao J; Gray SG; Greene CM; Lawless MW
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
    Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
    Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
    Gomazkov OA
    Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
    Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis.
    Kim HS; Shen Q; Nam SW
    J Korean Med Sci; 2015 Oct; 30(10):1375-80. PubMed ID: 26425032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.